Myocarditis: causes, mechanisms, and evolving therapies. (4th March 2023)

• Record Type: Journal Article
• Authors: Kyaw, Tin; Drummond, Grant; Bobik, Alex; Peter, Karlheinz
• Is Part Of: Expert opinion on therapeutic targets. Volume 27:Number 3(2023)
• Page Start: 225
• Page End: 238
• Publication Date: 2023-03-04
• Subjects: Myocarditis -- virus -- vaccine -- immune checkpoint inhibitors -- mRNA vaccines -- immunotherapy; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2023.2193330
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction: Myocarditis is a severe lymphocyte-mediated inflammatory disorder of the heart, mostly caused by viruses and immune checkpoint inhibitors (ICIs). Recently, myocarditis as a rare adverse event of mRNA vaccines for SARS-CoV-2 has caused global attention. The clinical consequences of myocarditis can be very severe, but specific treatment options are lacking or not yet clinically proven. Areas covered: This paper offers a brief overview of the biology of viruses that frequently cause myocarditis, focusing on mechanisms important for viral entry and replication following host infection. Current and new potential therapeutic targets/strategies especially for viral myocarditis are reviewed systematically. In particular, the immune system in myocarditis is dissected with respect to infective viral and non-infective, ICI-induced myocarditis. Expert opinion: Vaccination is an excellent emerging preventative strategy for viral myocarditis, but most vaccines still require further development. Anti-viral treatments that inhibit viral replication need to be considered following viral infection in host myocardium, as lower viral load reduces inflammation severity. Understanding how the immune system continues to damage the heart even after viral clearance will define novel therapeutic targets/strategies. We propose that viral myocarditis can be best treated using a combination of antiviral agents and immunotherapies that control cytotoxic T cell activity.